These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 2069490)

  • 1. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.
    Bradwejn J; Koszycki D; Shriqui C
    Arch Gen Psychiatry; 1991 Jul; 48(7):603-10. PubMed ID: 2069490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.
    Bradwejn J; Koszycki D; Couëtoux du Tertre A; van Megen H; den Boer J; Westenberg H
    Arch Gen Psychiatry; 1994 Jun; 51(6):486-93. PubMed ID: 8192551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder.
    Bradwejn J; Koszycki D; Annable L; Couëtoux du Tertre A; Reines S; Karkanias C
    Biol Psychiatry; 1992 Nov; 32(10):903-12. PubMed ID: 1467375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of aging on cholecystokinin-induced panic.
    Flint AJ; Koszycki D; Vaccarino FJ; Cadieux A; Boulenger JP; Bradwejn J
    Am J Psychiatry; 1998 Feb; 155(2):283-5. PubMed ID: 9464213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings.
    Wiedemann K; Jahn H; Yassouridis A; Kellner M
    Arch Gen Psychiatry; 2001 Apr; 58(4):371-7. PubMed ID: 11296098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder.
    Bradwejn J; Koszycki D; Meterissian G
    Can J Psychiatry; 1990 Feb; 35(1):83-5. PubMed ID: 2180549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity to cholecystokinin-tetrapeptide in major depression.
    Koszycki D; Copen J; Bradwejn J
    J Affect Disord; 2004 Jun; 80(2-3):285-90. PubMed ID: 15207943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose ranging study of the effects of cholecystokinin in healthy volunteers.
    Bradwejn J; Koszycki D; Bourin M
    J Psychiatry Neurosci; 1991 Jul; 16(2):91-5. PubMed ID: 1911739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emotional and cognitive factors connected with response to cholecystokinin tetrapeptide in healthy volunteers.
    Aluoja A; Shlik J; Vasar V; Kingisepp PH; Jagomägi K; Vasar E; Bradwejn J
    Psychiatry Res; 1997 Jan; 66(1):59-67. PubMed ID: 9061804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of low-dose cholecystokinin on respiratory function in healthy volunteers.
    Schruers K; Caycedo N; Overbeek T; Büchold H; Bourin M; Griez E
    Eur Neuropsychopharmacol; 2000 Sep; 10(5):419-21. PubMed ID: 10974616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings.
    Bradwejn J; Koszycki D; Payeur R; Bourin M; Borthwick H
    Am J Psychiatry; 1992 Jul; 149(7):962-4. PubMed ID: 1609879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central cholecystokinin activity in irritable bowel syndrome, panic disorder, and healthy controls.
    Koszycki D; Torres S; Swain JE; Bradwejn J
    Psychosom Med; 2005; 67(4):590-5. PubMed ID: 16046372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ventilatory response to cholecystokinin tetrapeptide in healthy volunteers.
    Katzman MA; Duffin J; Shlik J; Bradwejn J
    Neuropsychopharmacology; 2002 Jun; 26(6):824-31. PubMed ID: 12007753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.
    Bradwejn J; Koszycki D; Paradis M; Reece P; Hinton J; Sedman A
    Biol Psychiatry; 1995 Dec; 38(11):742-6. PubMed ID: 8580227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct panicogenic activity of sodium lactate and cholecystokinin tetrapeptide in patients with panic disorder.
    Plag J; Gaudlitz K; Zschucke E; Yassouridis A; Pyrkosch L; Wittmann A; Holsboer F; Ströhle A
    Curr Pharm Des; 2012; 18(35):5619-26. PubMed ID: 22632477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI.
    Schunck T; Mathis A; Erb G; Namer IJ; Hode Y; Demazières A; Luthringer R
    J Psychopharmacol; 2011 Jan; 25(1):52-9. PubMed ID: 20498136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder.
    Kellner M; Wiedemann K; Yassouridis A; Levengood R; Guo LS; Holsboer F; Yehuda R
    Biol Psychiatry; 2000 Jan; 47(2):107-11. PubMed ID: 10664826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks.
    Raedler TJ; Jahn H; Goedeken B; Gescher DM; Kellner M; Wiedemann K
    Depress Anxiety; 2006; 23(3):139-44. PubMed ID: 16470820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder.
    van Megen HJ; Westenberg HG; Den Boer JA; Kahn RS
    Eur Neuropsychopharmacol; 1996 Aug; 6(3):187-94. PubMed ID: 8880078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients.
    van Megen HJ; Westenberg HG; den Boer JA; Haigh JR; Traub M
    Psychopharmacology (Berl); 1994 Apr; 114(3):449-55. PubMed ID: 7855203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.